SCHEMBL141610

SCHEMBL141610

C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SERPINA6 P08185 6/20 0.80
▸ FNTA P49354 1/20 0.75
▸ FNTB P49356 1/20 0.75
▸ SMN1; SMN2 Q16637 9/20 0.72
▸ LMNA P02545 8/20 0.72
▸ ALDH1A1 P00352 7/20 0.72
▸ CYP3A4 P08684 7/20 0.72
▸ HSD17B10 Q99714 5/20 0.72
▸ SHBG P04278 5/20 0.72
▸ MAPT P10636 5/20 0.72
▸ MAPK1 P28482 4/20 0.72
▸ ABCB11 O95342 2/20 0.72
▸ HIF1A Q16665 4/20 0.67
▸ TSHR P16473 4/20 0.67
▸ CYP2C9 P11712 3/20 0.67
▸ NR3C2 P08235 3/20 0.67
▸ SLC22A2 O15244 2/20 0.67
▸ SLC22A1 O15245 2/20 0.67
▸ SLC22A3 O75751 2/20 0.67
▸ THPO P40225 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13026136 1.00 SERPINA6 (0.80) SERPINA6FNTAFNTBSMN1; SMN2LMNA
SCHEMBL14382323 1.00 SERPINA6 (0.80) SERPINA6FNTAFNTBSMN1; SMN2LMNA
SCHEMBL141611 1.00 SERPINA6 (0.80) SERPINA6FNTAFNTBSMN1; SMN2LMNA
SCHEMBL20239320 1.00 SERPINA6 (0.80) SERPINA6FNTAFNTBSMN1; SMN2LMNA
SCHEMBL9073248 0.91 SERPINA6 (0.79) SERPINA6FNTAFNTBSMN1; SMN2LMNA
SCHEMBL8751542 0.90 FNTA (0.81) SERPINA6FNTAFNTBSMN1; SMN2LMNA
SCHEMBL668966 0.89 SERPINA6 (1.00) SERPINA6FNTAFNTBSMN1; SMN2LMNA
SCHEMBL15904593 0.89 SERPINA6 (1.00) SERPINA6FNTAFNTBSMN1; SMN2LMNA
SCHEMBL14525642 0.89 SERPINA6 (1.00) SERPINA6FNTAFNTBSMN1; SMN2LMNA
SCHEMBL15920543 0.89 SERPINA6 (1.00) SERPINA6FNTAFNTBSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260148848-A1 BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2026-05-28 — — US claimed
EP-4709842-A1 SERUM-FREE AND XENO-FREE CULTURE MEDIUM FOR EXPANDING MESENCHYMAL STEM CELLS Nuwacell Biotechnologies Co., Ltd. (CN) 2026-03-18 — — EP claimed
US-12359173-B2 Serum-free and xeno-free culture medium for expanding mesenchymal stem cells NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) 2025-07-15 — — US claimed
EP-4562182-A1 BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2025-06-04 — — EP claimed
US-20250164507-A1 COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CARDIOMYOPATHY IN A FELINE Société des Produits Nestlé S.A. (CH) 2025-05-22 — — US claimed
WO-2025104511-A1 COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CARDIOMYOPATHY IN A FELINE SOCIETE DES PRODUITS NESTLE SA (CH) 2025-05-22 — — WO claimed
US-20250041208-A1 NEW INJECTABLE COMBINATION FORMULATION NANEXA AB (SE) 2025-02-06 — — US claimed
WO-2024229624-A1 SERUM-FREE AND XENO-FREE CULTURE MEDIUM FOR EXPANDING MESENCHYMAL STEM CELLS NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) 2024-11-14 — — WO claimed
US-20240368554-A1 SERUM-FREE AND XENO-FREE CULTURE MEDIUM FOR EXPANDING MESENCHYMAL STEM CELLS NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) 2024-11-07 — — US claimed
EP-4444277-A1 NEW INJECTABLE COMBINATION FORMULATION Nanexa AB (SE) 2024-10-16 — — EP claimed
EP-0122151-A2 Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique MEITO SANGYO KABUSHIKI KAISHA (JP) 1984-10-17 — — EP claimed
EP-0120557-A2 21-Hydroxycorticosteroid esters, and compositions containing them THE UPJOHN COMPANY (US) 1984-10-03 — — EP claimed
US-4472392-A Sulfonate containing ester prodrugs of corticosteroids THE UPJOHN COMPANY (US) 1984-09-18 — — US claimed
US-4469689-A WATER SOLUBLE, ANTIINFLAMMATORY AGENTS THE UPJOHN COMPANY (US) 1984-09-04 — — US claimed
US-4456602-A SOLUTION STABLE ANTIINFLAMMATORY AGENTS THE UPJOHN COMPANY (US) 1984-06-26 — — US claimed
EP-0106453-A1 21-Hydroxycorticosteroid esters, and compositions containing them THE UPJOHN COMPANY (US) 1984-04-25 — — EP claimed
US-4443440-A ANTIINFLAMMATORY AGENTS THE UPJOHN COMPANY (US) 1984-04-17 — — US claimed
EP-0104746-A1 21-Hydroxycorticosteroid esters, and compositions containing them THE UPJOHN COMPANY (US) 1984-04-04 — — EP claimed
US-4391803-A STEROID BLEND HEPAR INDUSTRIES (US) 1983-07-05 — — US claimed
US-4283394-A ANTICARCINOGENIC AGENTS RESEARCH CORPORATION (US) 1981-08-11 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260148848-A1 BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF SHBG, HSD11B2, HSD11B1 SERPINA6 8/4885FNTA 271/4885FNTB 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback